Keitaro Fukuda

9PUBLICATIONS
24CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersRespiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 15, 2023
IFNγ score-based neoadjuvant immunotherapy for stage III melanoma.

Keitaro Fukuda

|Jul 25, 2022
Cutaneous eyelid melanoma with lacrimal sac metastasis: the potential role of lacrimal fluid as a metastatic pathway.

Yoshio Nakamura, Keiji Tanese, Kaori Kameyama

|Apr 25, 2022
Management and outcomes of hydronephrosis in patients with metastatic extramammary Paget's disease: A retrospective analysis.

Takayuki Fusumae, Keitaro Fukuda, Ikuko Hirai

|Jul 29, 2021
AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma.

Keitaro Fukuda, Ken Okamura, Rebecca L Riding

|Oct 11, 2020
Type I interferon signaling limits viral vector priming of CD8+ T cells during initiation of vitiligo and melanoma immunotherapy.

Rebecca L Riding, Jillian M Richmond, Keitaro Fukuda

Pageof 2